218 related articles for article (PubMed ID: 34311724)
1. Transcriptional landscape of PTEN loss in primary prostate cancer.
Imada EL; Sanchez DF; Dinalankara W; Vidotto T; Ebot EM; Tyekucheva S; Franco GR; Mucci LA; Loda M; Schaeffer EM; Lotan T; Marchionni L
BMC Cancer; 2021 Jul; 21(1):856. PubMed ID: 34311724
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort.
Morais CE; Gurgel DC; Teixeira AC; Mattos TVA; Silva AVAD; Tavora F
Braz J Med Biol Res; 2019; 52(12):e8483. PubMed ID: 31826177
[TBL] [Abstract][Full Text] [Related]
3. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
[TBL] [Abstract][Full Text] [Related]
4. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
5. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
[TBL] [Abstract][Full Text] [Related]
6. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
7. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
Tosoian JJ; Almutairi F; Morais CL; Glavaris S; Hicks J; Sundi D; Humphreys E; Han M; De Marzo AM; Ross AE; Tomlins SA; Schaeffer EM; Trock BJ; Lotan TL
Eur Urol; 2017 May; 71(5):697-700. PubMed ID: 27477529
[TBL] [Abstract][Full Text] [Related]
9. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
10. Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer.
Mahdian R; Nodouzi V; Asgari M; Rezaie M; Alizadeh J; Yousefi B; Shahrokh H; Abolhasani M; Nowroozi M
Mol Biol Rep; 2014 Sep; 41(9):6125-31. PubMed ID: 24985972
[TBL] [Abstract][Full Text] [Related]
11. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
12. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
13. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
[TBL] [Abstract][Full Text] [Related]
14. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.
Shah RB; Bentley J; Jeffery Z; DeMarzo AM
Hum Pathol; 2015 May; 46(5):698-706. PubMed ID: 25724568
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.
Reid AH; Attard G; Ambroisine L; Fisher G; Kovacs G; Brewer D; Clark J; Flohr P; Edwards S; Berney DM; Foster CS; Fletcher A; Gerald WL; Møller H; Reuter VE; Scardino PT; Cuzick J; de Bono JS; Cooper CS;
Br J Cancer; 2010 Feb; 102(4):678-84. PubMed ID: 20104229
[TBL] [Abstract][Full Text] [Related]
18. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
[TBL] [Abstract][Full Text] [Related]
19. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.
Hashim D; Gonzalez-Feliciano AG; Ahearn TU; Pettersson A; Barber L; Pernar CH; Ebot EM; Isikbay M; Finn SP; Giovannucci EL; Lis RT; Loda M; Parmigiani G; Lotan T; Kantoff PW; Mucci LA; Graff RE
Int J Cancer; 2020 May; 146(10):2694-2702. PubMed ID: 31318977
[TBL] [Abstract][Full Text] [Related]
20. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
